References
- Carson S L. Efficacy and clinical profile of a new oral contraceptive containing norgestimate: U.S. clinical trials. Acta Obstet Gynecol Scand Suppl 1990; 152: 25–31
- Burkman R T., Kafrissen M E., Olson W, Osterman J. Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl 1992; 71: 5–8
- Vessey M, Metcalfe A, Wells C, et al. Ovarian neoplasms, functional ovarian cysts, and oral contraceptives. Br Med J 1987; 294: 1518–20
- Eyong E, Buchi K, Elstein M. Effects of 180 μg and 250 μg norgestimate on pituitary-ovarian function and cervical mucus. Fertil Steril 1988; 50: 756–60
- Phillips A, Demarest K, Hahn D W., et al. Progestational and androgenic receptor binding affinities and in vivo activities of norgestimate and other progestins. Contraception 1990; 41(4)399–410
- Chapdelaine A, Desmarais J L., Derman R J. Clinical evidence of the minimal androgenic activity of. norgestimate. Int J Fertil 1989; 34: 347–52